Skip to main content

Advertisement

SpringerLink
Log in

Neue Aspekte in der Therapie von Schilddrüsenkarzinomen

Highlights des ASCO-Kongresses 2015

New aspects in thyroid cancer treatment

Highlights of the ASCO Annual Meeting 2015

  • Leitthema
  • Published:
HNO Aims and scope Submit manuscript

Zusammenfassung

Anfang Juni 2015 fand der jährliche Kongress der American Society of Clinical Oncology (ASCO) in Chicago statt. Insgesamt wurden 24 Studien im Bereich der Schilddrüsenkarzinome vorgestellt, die in diesem Übersichtsartikel nach dem Grad der Differenzierung gruppiert sind. Die führende kurative Therapiemodalität ist nach wie vor die chirurgische Behandlung. Kinaseinhibitoren werden vor allem im Rahmen eines palliativen Konzeptes angewendet. Der neueste Stand der Wissenschaft zur Therapie von Schilddrüsenkarzinomen, sowohl chirurgisch als auch internistisch, wird nachfolgend zusammengefasst.

Abstract

At the beginning of June 2015, the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in Chicago. A total of 24 studies in the field of thyroid oncology were presented, being discussed in the present review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. Kinase inhibitors are used primarily in the context of palliative treatment concepts. The most recent treatment options in thyroid oncology, both surgical and medical, are summarized in the following article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Wei T, Chen R, Zou X, Liu F, Li Z, Zhu J (2015) Predictive factors of contralateral paratracheal lymph node metastasis in unilateral papillary thyroid carcinoma. ASCO Meet Abstr 33(15 suppl):e17005

    Google Scholar 

  2. Su A, Wei T, Liu F, Gong Y, Ma Y, Wen L, Zou X, Gong R, Li Z, Zhu J (2015) Use of carbon nanoparticles to identify parathyroid glands at thyroidectomy for patients of papillary thyroid cancer. ASCO Meet Abstr 33(15 suppl):e17006

    Google Scholar 

  3. Markovic I, Dzodic R, Oruci M, Buta M, Djurisic I, Pupic G, Nikolic S, Inic Z, Santrac N, Markovic M, Kocic M, Tomasevic Z (2015) Sentinel lymph node biopsy in papillary thyroid cancer: reliability in decision for selective lateral neck dissection. ASCO Meet Abstr 33(15 suppl):e17022

    Google Scholar 

  4. Oruci M, Markovic I, Santrac N, Djurisic I, Buta M, Pupic G, Gavrilovic D, Dzodic R (2015) Incidence of lymphonodal metastases in thyroid microcarcinomas. Asco Meet Abstr 33(15 suppl):e17032

    Google Scholar 

  5. Shang J, Wang J, Gu J, Wang W, Han Q, Wang K (2015) Value of intraoperative parathyroid hormone monitoring in papillary thyroid cancer surgery: can it be used to guide the choice of operation methods? ASCO Meet Abstr 33(15 suppl):e17026

    Google Scholar 

  6. He Q (2015) Comparative study comparing robotic thyroidectomy plus central neck dissection using the axillo-bilateral-breast approach and open conventional thyroidectomy for papillary thyroid microcarcinoma. ASCO Meet Abstr 33(15 suppl):e17031

    Google Scholar 

  7. Brose MS, Schlumberger M, Tahara M, Wirth LJ, Robinson B, Elisei R, Newbold K, Kiyota N, Hoff AO, Dutcus C, Song J, Sherman SI, Taylor MH (2015) Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT. ASCO Meet Abstr 33(15 suppl):6048

    Google Scholar 

  8. Brose MS, Troxel AB, Yarchoan M, Cohen AB, Harlacker K, Dyanick NA, Posey ZA, Makani R, Prajapati P, Zifchak LM, Grande C, Squillante CM (2015) A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone. ASCO Meet Abstr 33(15 suppl):6072

    Google Scholar 

  9. Kappeler C, Healy DP, Baumer C, Meinhardt G, Elisei R, Schlumberger M, Brose MS (2015) Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study. ASCO Meet Abstr 33(15 suppl):6015

    Google Scholar 

  10. Newbold K, Elisei R, Taylor MH, Krzyzanowska MK, Shah MH, Hoff AO, Robinson B, Dutcus C, Song J, Habra MA (2015) Efficacy and safety of lenvatinib for the treatment of patients with131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy. ASCO Meet Abstr 33(15 suppl):6013

    Google Scholar 

  11. Sherman EJ, Ho AL, Fury MG, Baxi SS, Dunn L, Lee JS, Lipson BL, Pfister DG (2015) Combination of everolimus and sorafenib in the treatment of thyroid cancer: update on phase II study. ASCO Meet Abstr 33(15 suppl):6069

    Google Scholar 

  12. Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Dutcus C, Xu J, Zhu J, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI (2015) Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT). ASCO Meet Abstr 33(15 suppl):6014

    Google Scholar 

  13. Dunn L, Ho AL, Haque S, Fury MG, Baxi SS, Cullen G, Pfister DG, Sherman EJ (2015) Assessment of second-line VEGF-inhibitor therapy in radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC). ASCO Meet Abstr 33(15 suppl):17064

    Google Scholar 

  14. Suman P, Moo-Young T, Prinz RA, Winchester DJ (2015) Association of sociodemographic factors with nonguideline treatment in papillary thyroid carcinoma. ASCO Meet Abstr 33(15 suppl):e17096

    Google Scholar 

  15. Uziely B, Ratzon N, Rottenberg Y (2015) Unemployment risk and decreased income 2 and 4 years after thyroid cancer diagnosis: a population based study. ASCO Meet Abstr 33(15 suppl):e20618

    Google Scholar 

  16. Torres A, Martaan E, Torres A, Torres A (2015) Chemotherapy effectiveness in the treatment of non-medullary well-differentiated thyroid cancer: A systematic review. ASCO Meet Abstr 33(15):17058

    Google Scholar 

  17. Sherman SI, Pagan M, Huang J, Lin B, Diggans J, Tom E, Haugen B, Tuttle RM, Kennedy G (2015) Augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma using machine learning and high dimensional transcriptional data from thyroid FNA. ASCO Meet Abstr 33(15 suppl):6044

    Google Scholar 

  18. Capdevila J, Vivancos A, Matias-Guiu X, Iglesias C, Salva F, Serres X, Gonzalez O, Caubet E, Jimenez J, Zafon C, Mancuso FM, Caratu G, Alvarez C, Mayor R, Tabernero J, Seoane J (2015) Genomic landscape of anaplastic thyroid cancer. ASCO Meet Abstr 33(15 suppl):6033

    Google Scholar 

  19. Johnson JM, Chen J, Dardi IK, Tuluc M, Ali SM, Cognetti D, Campling BG, Sama AR (2015) Molecular profile of synchronous metastatic colon cancer and anaplastic thyroid cancer in a patient with Lynch Syndrome. ASCO Meet Abstr 33(15 suppl):e22049

    Google Scholar 

  20. Khan SA, Bauman JE, Burtness B, Frankel AE, Harper J, Hughes RS, Kurian P, Myers LL, Nedzi LA, Schwartz DL, Sumer BD, Truelson J, Zhu H (2015) Ceritinib in anaplastic thyroid cancer (ATC) with ALK abnormalities. ASCO Meet Abstr 33(15 suppl):TPS6085

    Google Scholar 

  21. Yilmaz E, Champa D, Di Cristofano A (2015) Synergistic effect of combined PI3K and PLK1 inhibition in anaplastic thyroid carcinoma cells. ASCO Meet Abstr 33(15 suppl):e22205

    Google Scholar 

  22. Dean AP, Goh RYH, Smith P (2015) Anaplastic Thyroid Cancer: a report of 5 consecutive cases treated successfully with nab-Paclitaxel. ASCO Meet Abstr 33(15 suppl):e17095

    Google Scholar 

  23. Schlumberger M, Elisei R, Muller S, Schoffski P, Brose MS, Shah MH, Licitra LF, Jarzab B, Medvedev V, Kreissl M, Cohen EEW, Wirth LJ, Ali HY, Hessel C, Yaron Y, Ball DW, Nelkin B, Sherman SI (2015) Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. ASCO Meet Abstr 33(15 suppl):6012

    Google Scholar 

  24. Malone ER, Gallagher DJ (2015) The rate of RET mutation testing in medullary thyroid cancer in the Republic of Ireland. ASCO Meet Abstr 33(15 suppl):e12516

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Univ.-Klinik für HNO Heilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Deutschland

    B.B. Lörincz &  R. Knecht

  2. Univ.-Klinik für Allgemein-, Viszeral- und Kinderchirurgie, Universitätsklinikum Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, Deutschland

    S. Topp

Authors
  1. B.B. Lörincz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Topp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Knecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Knecht.

Ethics declarations

Interessenkonflikt

B. B. Lörincz, S. Topp und R. Knecht geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lörincz, B., Topp, S. & Knecht, R. Neue Aspekte in der Therapie von Schilddrüsenkarzinomen. HNO 63, 625–628 (2015). https://doi.org/10.1007/s00106-015-0052-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-015-0052-3

Schlüsselwörter

Keywords

Search

Navigation